Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...
For the past 18 months, Rubius Therapeutics has been quietly stitching itself together into a new biotech looking to pioneer a radically new technology: turning hematopoietic stem cells into red blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback